Why the study?
The study was conducted to investigate the putative association between semaglutide and non-arteritic anterior ischaemic optic neuropathy.
Does semaglutide increase the risk of NAION compared to SGLT-2is in individuals with type 2 diabetes?
Does semaglutide increase the risk of NAION compared to SGLT-2is in individuals with type 2 diabetes?
Semaglutide use for managing type 2 diabetes is associated with a significantly increased relative risk of NAION compared to SGLT-2is, although the absolute risk remains low.
Answers are grounded in this paper and cite their sources.
Semaglutide may raise NAION risk versus SGLT-2is in T2D; hypothesis-generating and requires randomized confirmation before practice change.
AIMS: To investigate the putative association between semaglutide and non-arteritic anterior ischaemic optic neuropathy (NAION). MATERIALS AND METHODS: Data from national health registries in Denmark (2018-2024) and Norway (2018-2022) were used to compare NAION risk in individuals with type 2 diabetes initiating semaglutide versus sodium-glucose co-transporter 2 inhibitors (SGLT-2is). A supplementary self-controlled analysis examined NAION risk among all semaglutide users. National estimates were pooled using a fixed-effects model. RESULTS: We identified 44 517 users of semaglutide for the management of type 2 diabetes in Denmark and 16 860 in Norway, with a total of 32 NAION events observed. The unadjusted incidence rate of NAION was 2.19/10 000 person-years among Danish semaglutide initiators, compared to 1.18 among SGLT-2i initiators. In Norway, the corresponding rates were 2.90 and 0.92, respectively. After adjustment, the pooled hazard ratio (HR) was 2.81 (95% confidence interval [CI] 1.67-4.75), and the incidence rate difference (IRD) was +1.41 (95% CI +0.53 to +2.29) per 10 000 person-years. Estimates were consistent across both countries but higher and less precise in Norway (HR 7.25; 95% CI 2.34-22.4) compared to Denmark (HR 2.17; 95% CI 1.20-3.92). Results remained consistent across sensitivity and supplementary analyses, with a stronger association observed in a post hoc per-protocol analysis (HR 6.35; 95% CI 2.88-14.0). In the supplementary self-controlled study, symmetry ratios (SRs) for NAION were 1.14 (95% CI 0.55-2.36) in Denmark and 2.67 (95% CI 0.91-8.99) in Norway. CONCLUSIONS: The use of semaglutide for managing type 2 diabetes is associated with an increased risk of NAION compared with the use of SGLT-2is. However, the absolute risk remains low.
No takes yet. Share an insight, caveat, or question.
Simonsen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: